Learn more

CHEN ING-JUN

Overview
  • Total Patents
    19
About

CHEN ING-JUN has a total of 19 patent applications. Its first patent ever was published in 1999. It filed its patents most often in United States, Taiwan and United Kingdom. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and macromolecular chemistry and polymers are RAPT THERAPEUTICS INC, OOO KONSORTSIUM PIK and RECORDATI IND CHIMICA E FARMACEUTICA S P A.

Patent filings in countries

World map showing CHEN ING-JUNs patent filings in countries
# Country Total Patents
#1 United States 11
#2 Taiwan 7
#3 United Kingdom 1

Patent filings per year

Chart showing CHEN ING-JUNs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Chen Ing-Jun 19

Latest patents

Publication Filing date Title
TW201509417A Use of jenstadin-analogs for improving feed-efficiency and reducing feeding-rate
TW201416075A Use of jenstadin-analogs for improving feed-efficiency and reducing feeding-rate and adipose-tissue weight of obesity animal
US2013095059A1 Inhaled no donor kmups derivative preventing allergic pulmonary vascular and bronchial inflammation via suppressed cytokines, inos and inflammatory cell counts in asthma model
US2011136767A1 Processes for preparing piperazinium salts of KMUP and use thereof
TW200740439A Relaxation of prostate by KMUP-1 involves α 1A adrenoceptor blockade and K+ -channel opening, indicating useful to relief benigh prostate hyperplasty-induced urinary obstruction
TW200800245A Herbal preparation (HBHPBaicalin), rich in baicalin and useful in gargles, candy, toothgel and anti-acne preparations, displaying anti-inflammatory and anti-bacterial activities
TW200706176A N7-substituted xanthine derivatives
US2005209243A1 Theophylline-based soluble guanylyl cyclase activators KMUP-1 analogues enhanced cyclic GMP and K+ channel activities on rabbit corpus cavernosum smooth muscle and intercavernous pressure activities
US2005209242A1 Theophylline and 3-isobutyl-1 methylxanthine based N-7 substituted derivatives displaying inhibitory activities on PDE-5 phospodiesterase
US6846826B2 Phenoxypropanol connected with phenylpiperazine and phenoxyalkylamine terminal in its side chain
TWI268930B Theophylline and 3-isobutyl-1-methylxanthine based N-7 substituted derivatives and pharmaceutical composition thereof
TWI251589B N7-substituted xanthine derivatives